A urinary DNA assay for bladder cancer, strong except early

Design

Prospective multicentre diagnostic accuracy study (training and validation cohorts)

Population

502 participants (302 bladder cancer, 200 controls) at two tertiary hospitals

Primary outcome

Urinary DNA mutation and methylation assay versus cystoscopy and histology

Effect

Sensitivity 85.9%, specificity 95.8%; early-stage sensitivity 70.3%

Cystoscopy remains the standard for bladder cancer diagnosis and surveillance but is invasive, and existing urine tests underperform. This study developed EpiMut-BC, a urinary assay combining DNA mutation and methylation signatures read by a modified real-time PCR method, and tested it prospectively.

Across 502 participants at two tertiary hospitals (302 with histologically confirmed bladder cancer, 200 controls), the assay reached 85.9% sensitivity, 95.8% specificity and 89.8% accuracy against cystoscopy and histology. Performance held across control subgroups, but sensitivity fell to 70.3% for early-stage tumours and 81.7% for superficial tumours.

For laboratory practice this is a promising adjunct: a positive result is fairly trustworthy given the high specificity, and the assay could reduce repeated cystoscopy in surveillance. The weak point is early disease, where nearly a third of tumours were missed, so a negative urine result cannot yet stand in for cystoscopy in a patient with real suspicion.

• Prospective two-centre study of a urinary DNA mutation-plus-methylation assay in 502 participants.
• Overall sensitivity 85.9%, specificity 95.8%, accuracy 89.8% against cystoscopy and histology.
• Early-stage sensitivity was 70.3% and superficial-tumour sensitivity 81.7%.
• High specificity makes a positive result useful and could cut repeat cystoscopy in surveillance.
• A negative result cannot yet replace cystoscopy where suspicion of early disease is real.

Why it matters

A reliable urine test would spare patients repeated invasive cystoscopy, but only if its miss rate in early disease is understood.

Don't overread it

This was a two-centre cohort from one country, and early-stage sensitivity near 70% means a negative result does not exclude bladder cancer.

The statistics, in plain English

High specificity (96%) means few false positives, so a positive test is informative; the 70% early-stage sensitivity means a negative test misses almost a third of early cancers, which is why it supplements rather than replaces cystoscopy.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.